期刊文献+

中国痴呆与认知障碍诊治指南(四):辅助检查及其选择 被引量:6

原文传递
导出
摘要 在痴呆的诊断流程中,辅助检查是必需的,能为我们确定痴呆和认知障碍的类型提供有力的证据.辅助检查包括体液检查、影像学检查、电生理检查、基因检查,各项检查在不同痴呆和认知障碍类型诊断中价值也不相同,正确理解和判读显得十分重要.
出处 《中华医学杂志》 CAS CSCD 北大核心 2011年第13期867-875,共9页 National Medical Journal of China
基金 "十一五"国家科技支撑计划基金(2006BAI02B01)
  • 相关文献

参考文献104

  • 1Gustaw-Rothenberg K,Lerner A,Bonda DJ,et al.Biomarkers in Alzheimer's disease:past,present and future.Biomark Med,2010,4:15-26.
  • 2Schneider P,Hampel H,Buerger K.Biological marker candidates of Alzheimer's disease in blood,plasma,and serum.CNS Neurosci Ther,2009,15:358-374.
  • 3Mulder C,Verwey NA,van der Flier WM,et al.Amyloid-beta(142),total tau,and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease.Clin Chem,2010,56:248-253.
  • 4Stomrud E,Hansson O,Zetterberg H,et al.Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults.Arch Neurol,2010,67:217-223.
  • 5Blennow K,Hampel H.CSF markers for incipient Alzheimer's disease.Lancet Neurol,2003,2:605-613.
  • 6Schoonenboom NS,Pijnenburg YA,Mulder C,et al.Amyloid beta (1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease.Neurology,2004,62:1580-1584.
  • 7Riemenschneider M,Wagenpfeil S,Diehl J,et al.Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration.Neurology,2002,58:1622-1628.
  • 8Kanemasu K,Kameda N,Yamanouchi H.Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies.Neurology,2000,54:1875-1876.
  • 9Hulstaert F,Blennow K,lvanoiu A,et al.Improved discrimination of AD patients using beta-amyloid (1-42) and tau levels in CSF.Neurology,1999,52:1555-1562.
  • 10Nagga K,Gotffries J,Blennow K,et al.Cerebrospinal fluid phospho-tau,total tau and beta-amyloid (1-42) in the differentiation between Alzheimer's disease and vascular dementia.Dement Geriatr Cogn Disord,2002,14:183-190.

二级参考文献3

共引文献9

同被引文献109

引证文献6

二级引证文献192

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部